ELCC 2017 Management of Small-cell Lung Cancer

Speaker: Corinne Faivre-Finn

Corinne Faivre-Finn says that personalisation of limited stage SCLC patients’ treatment is the main challenge in this disease.Today the standard of care for stage I, II and III SCLC patients with good performance status is concurrent chemoradiotherapy, regardless of history or tumour size.

There is a lot to learn as to which groups would benefit the most or may develop severe toxicity from the treatment. Immunotherapy has shown some activity in stage IV patients and ongoing studies are looking at the integration of immunotherapy in the treatment of earlier stage patients. Today the safety and efficacy of immunotherapy combined with chemoradiotherapy in first stages SCLC patients still need to be established.

Discussion Points

  • Are there advances in the treatment of SCLC?
  • What are the key challenges?
  • Future outlook